Pyrotinib is Effective in Both Trastuzumab-sensitive and Primary Resistant HER2-positive Breast Tumors

Overview

Journal Chin J Cancer Res

Specialty Oncology

Date 2024 May 16

PMID 38751436

Authors

Jialin Zhang

Gengshen Yin

Chunmiao Ye

Man Feng

Changhua Ji

Wenzhong Zhou

Fei Wang

Lixiang Yu

Shuya Huang

Zhigang Yu

Affiliations

Soon will be listed here.

Abstract

Objective: Primary resistance to trastuzumab frequently occurs in human epidermal growth factor receptor 2 (HER2)-positive (+) breast cancer patients and remains a clinical challenge. Pyrotinib is a novel tyrosine kinase inhibitor that has shown efficacy in the treatment of HER2+ breast cancer. However, the efficacy of pyrotinib in HER2+ breast cancer with primary trastuzumab resistance is unknown.

Methods: HER2+ breast cancer cells sensitive or primarily resistant to trastuzumab were treated with trastuzumab, pyrotinib, or the combination. Cell proliferation, migration, invasion, and HER2 downstream signal pathways were analyzed. The effects of pyrotinib plus trastuzumab and pertuzumab plus trastuzumab were compared in breast cancer cells and a xenograft mouse model with primary resistance to trastuzumab.

Results: Pyrotinib had a therapeutic effect on trastuzumab-sensitive HER2+ breast cancer cells by inhibiting phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) and rat sarcoma virus (RAS)/rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MAPK)/extracellular-signal regulated kinase (ERK) pathways. In primary trastuzumab-resistant cells, pyrotinib inhibited cell growth, migration, invasion, and HER2 downstream pathways, whereas trastuzumab had no effects. The combination with trastuzumab did not show increased effects compared with pyrotinib alone. Compared with pertuzumab plus trastuzumab, pyrotinib plus trastuzumab was more effective in inhibiting cell proliferation and HER2 downstream pathways in breast cancer cells and tumor growth in a trastuzumab-resistant HER2+ breast cancer xenograft model.

Conclusions: Pyrotinib-containing treatments exhibited anti-cancer effects in HER2+ breast cancer cells sensitive and with primary resistance to trastuzumab. Notably, pyrotinib plus trastuzumab was more effective than trastuzumab plus pertuzumab in inhibiting tumor growth and HER2 downstream pathways in HER2+ breast cancer with primary resistance to trastuzumab. These findings support clinical testing of the therapeutic efficacy of dual anti-HER2 treatment combining an intracellular small molecule with an extracellular antibody.

Citing Articles

Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study.

Wang F, Wang Y, Xiong B, Yang Z, Wang J, Yao Y Signal Transduct Target Ther. 2025; 10(1):45.

PMID: 39875376 PMC: 11775149. DOI: 10.1038/s41392-025-02138-6.

References

Wu J, Jiang Z, Liu Z, Yang B, Yang H, Tang J . Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial. BMC Med. 2022; 20(1):498. PMC: 9795751. DOI: 10.1186/s12916-022-02708-3. View

Yin G, Liu L, Yu T, Yu L, Feng M, Zhou C . Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy. Genome Med. 2024; 16(1):11. PMC: 10787499. DOI: 10.1186/s13073-024-01286-8. View

Canonici A, Ivers L, Conlon N, Pedersen K, Gaynor N, Browne B . HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer. Invest New Drugs. 2018; 37(3):441-451. DOI: 10.1007/s10637-018-0649-y. View

Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea M . Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models. NPJ Breast Cancer. 2021; 7(1):63. PMC: 8159999. DOI: 10.1038/s41523-021-00274-0. View

Martin-Castillo B, Oliveras-Ferraros C, Vazquez-Martin A, Cufi S, Moreno J, Corominas-Faja B . Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin). Cell Cycle. 2012; 12(2):225-45. PMC: 3575452. DOI: 10.4161/cc.23274. View

Liu X, Liu J, Xu Y, Zhang X, Wang Y, Qing L . Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA accompanied with pro-tumorigenic secretome. Int J Cancer. 2019; 145(3):817-829. DOI: 10.1002/ijc.32153. View

Marti J, Nasrazadani A, Ding Y, Normolle D, Brufsky A . Twenty-Year Follow-Up of a Phase II Trial of Taxotere/Carboplatin/Herceptin in Patients With Metastatic HER2-Positive Breast Cancer. Oncologist. 2023; 28(11):e1123-e1126. PMC: 10628556. DOI: 10.1093/oncolo/oyad258. View

Zheng Y, Cao W, Shao X, Shi Y, Cai L, Chen W . Pyrotinib plus docetaxel as first-line treatment for HER2-positive metastatic breast cancer: the PANDORA phase II trial. Nat Commun. 2023; 14(1):8314. PMC: 10721794. DOI: 10.1038/s41467-023-44140-y. View

Huober J, Holmes E, Baselga J, de Azambuja E, Untch M, Fumagalli D . Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. Eur J Cancer. 2019; 118:169-177. DOI: 10.1016/j.ejca.2019.04.038. View

10.

Gijsen M, King P, Perera T, Parker P, Harris A, Larijani B . HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer. PLoS Biol. 2011; 8(12):e1000563. PMC: 3006345. DOI: 10.1371/journal.pbio.1000563. View

11.

Blair H . Pyrotinib: First Global Approval. Drugs. 2018; 78(16):1751-1755. DOI: 10.1007/s40265-018-0997-0. View

12.

Ma F, Li Q, Chen S, Zhu W, Fan Y, Wang J . Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer. J Clin Oncol. 2017; 35(27):3105-3112. DOI: 10.1200/JCO.2016.69.6179. View

13.

An W, Yao S, Sun X, Hou Z, Lin Y, Su L . Glucocorticoid modulatory element-binding protein 1 (GMEB1) interacts with the de-ubiquitinase USP40 to stabilize CFLAR and inhibit apoptosis in human non-small cell lung cancer cells. J Exp Clin Cancer Res. 2019; 38(1):181. PMC: 6498657. DOI: 10.1186/s13046-019-1182-3. View

14.

Li X, Yang C, Wan H, Zhang G, Feng J, Zhang L . Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer. Eur J Pharm Sci. 2017; 110:51-61. DOI: 10.1016/j.ejps.2017.01.021. View

15.

Xiang H, Xin L, Ye J, Xu L, Zhang H, Zhang S . A multicenter study on efficacy of dual-target neoadjuvant therapy for HER2-positive breast cancer and a consistent analysis of efficacy evaluation of neoadjuvant therapy by Miller-Payne and RCB pathological evaluation systems (CSBrS-026). Chin J Cancer Res. 2024; 35(6):702-712. PMC: 10774131. DOI: 10.21147/j.issn.1000-9604.2023.06.13. View

16.

Ye C, Zhou W, Wang F, Yin G, Zhang X, Kong L . Prognostic value of gamma-interferon-inducible lysosomal thiol reductase expression in female patients diagnosed with breast cancer. Int J Cancer. 2021; 150(4):705-717. DOI: 10.1002/ijc.33843. View

17.

Li J, Jiang Z . Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines in 2022: stratification and classification. Cancer Biol Med. 2022; 19(6). PMC: 9257320. DOI: 10.20892/j.issn.2095-3941.2022.0277. View

18.

Cao J, Teng Y, Li H, Zhang L, Ouyang Q, Xie W . Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial. BMC Med. 2023; 21(1):300. PMC: 10410905. DOI: 10.1186/s12916-023-02999-0. View

19.

Burguin A, Diorio C, Durocher F . Breast Cancer Treatments: Updates and New Challenges. J Pers Med. 2021; 11(8). PMC: 8399130. DOI: 10.3390/jpm11080808. View

20.

Zhao W, Bian L, Wang T, Zhang S, Li J, Xu F . Effectiveness of second-line anti-HER2 treatment in HER2-positive metastatic breast cancer patients previously treated with trastuzumab: A real-world study. Chin J Cancer Res. 2020; 32(3):361-369. PMC: 7369172. DOI: 10.21147/j.issn.1000-9604.2020.03.07. View